Nurix Therapeutics, Inc. NRIX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration revenue | $6.25M-66.1% | $13.58M+2.2% | $7.89M-37.3% | $14.06M+16.2% | $18.45M+11.3% | |
| License revenue | $30M— | —— | $15M— | $15M— | —— | |
| R&D by Product | ||||||
| Bexobrutideg (NX-5948) | $23.97M+52.5% | —— | —— | —— | $15.72M+66.0% | |
| Internal research and development expenses | $57.07M+12.2% | —— | —— | —— | $50.88M+17.4% | |
| NX-1607 | $1.19M-39.4% | —— | —— | —— | $1.96M+20.6% | |
| Zelebrudomide (NX-2127) | $1.91M+72.3% | —— | —— | —— | $1.11M+13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Nurix Therapeutics, Inc. break its business down?
- Nurix Therapeutics, Inc. (NRIX) reports revenue by product across 2 parts — Collaboration revenue and License revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Nurix Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Nurix Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
